Different regional dynamics of end-stage renal disease in Japan by different causes

Nephrology

Volumn 10, Issue 4, 2005, Pages 400-404

  Kato, Nobuo ^a   Usami, Takeshi ^a   Fukuda, Michio ^a   Motokawa, Masahiro ^a   Kamiya, Yoshinobu ^a   Yoshida, Atsuhiro ^a   Kimura, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chronic kidney disease; Diabetic nephropathy; End stage renal disease; Glomerulonephritis; Polycystic kidney disease; Regional difference

Indexed keywords

ARTICLE; CHRONIC GLOMERULONEPHRITIS; DIABETIC NEPHROPATHY; DIALYSIS; HUMAN; INCIDENCE; JAPAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

CHRONIC DISEASE; DIABETIC NEPHROPATHIES; GLOMERULONEPHRITIS; HUMANS; INCIDENCE; JAPAN; KIDNEY FAILURE, CHRONIC; POLYCYSTIC KIDNEY DISEASES; RISK FACTORS;

EID: 28444494306     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00404.x     Document Type: Article

References (32)

1. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA 2000; 284: 2622-4.
2. Usami T, Sato R, Yoshida A, Kimura G. Regional variation in end-stage renal disease. Curr. Opin. Nephrol. Hypertens. 2002; 11: 343-6.
3. Usami T, Nakao N, Fukuda M et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int. 2003; 64: 1445-9.
4. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 1986; 77: 1925-30.
5. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
7. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285: 2719-28.
8. Brenner BM. Retarding the progression of renal disease. Kidney Int. 2003; 64: 370-78.
9. Usami T, Nakao N, Fukuda M, Yoshida A, Kimura G. Renoprotective action of statin estimated from mapping renal failure in Japan. Kidney Int. 2004; 65: 1520.
10. Japanese Society for Dialysis Therapy. An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001). Tokyo: Japanese Society for Dialysis Therapy, 2003.
11. Rosansky SJ, Huntsberger TL, Jackson K, Eggers P. Comparative incidence rates of end-stage renal disease treatment by state. Am. J. Nephrol. 1990; 10: 198-204.
12. Foxman B, Moulton LH, Wolfe RA, Guire KE, Port FK, Hawthorne VM. Geographic variation in the incidence of treated endstage renal disease. J. Am. Soc. Nephrol. 1991; 2: 1144-52.
13. Cass A, Cunningham J, Wang Z, Hoy W. Regional variation in the incidence of end-stage renal disease in Indigenous Australians. Med. J. Aust. 2001; 175: 24-7.
14. Relman AS, Rennie D. Treatment of end-stage renal disease: Free but not equal. N. Engl. J. Med. 1980; 303: 996-8.
15. United States Renal Data System: USRDS 2003 Annual Data Report. Bethesda, MD: US Department of Health and Human Services, 2003.
16. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N. Engl. J. Med. 1982; 306: 1276-9.
17. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch. Intern. Med. 1991; 151: 1359-64.
18. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293-8.
19. Pugh JA, Stern MP, Haffner SM, Eifler CW, Zapata M. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am. J. Epidemiol. 1988; 127: 135-44.
20. Feldman HI, Klag MJ, Chiapella AP, Whelton PK. End-stage renal disease in US minority groups. Am. J. Kidney Dis. 1992; 19: 397-410.
21. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992; 42: 1259-65.
22. Kennefick TM, Al-Nimri MA, Oyama TT et al. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int. 1999; 56: 2181-90.
23. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1994; 5: 1349-54.
24. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
25. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2003; 18: 2314-20.
26. Schrier R, McFann K, Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J. Am. Soc. Nephrol. 2002; 13: 1733-939.
27. Klahr S, Breyer JA, Beck GJ et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 1995; 5: 2037-47.
28. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2002; 35: 427-32.
29. Rosman JB, Langer K, Brandl M et al. Protein-restricted diets in chronic renal failure: A four year follow-up shows limited indications. Kidney Int. 1989; 27 (Suppl.): S96-S102.
30. Jafar TH, Stark PC, Schmid CH et al. The effect of angiotensin- converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005; 67: 265-71.
31. Ecder T, Edelstein CL, Fick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 2001; 21: 98-103.
32. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J. Am. Soc. Nephrol. 2003; 14: 2902-7.